Abstract

Background & aims: Therapeutic drug monitoring might be used to personalize infliximab treatment of patients with ulcerative colitis (UC), although exposure thresholds associated with endoscopic healing are uncertain. We aimed to determine infliximab concentration thresholds associated with endoscopic outcomes during induction and maintenance therapy for patients with UC.

Tags

ACT-1, ACT-2, Anti-TNF, Colonoscopy, Drug Therapy, Exposure-Based Dosing, Gastrointestinal Agents, Infliximab, Intestinal Mucosa, Pathology, Pharmacokinetics, Therapeutic drug monitoring, therapeutic use, Treatment Outcome, Ulcerative Colitis

Read More